ERBB2 is amplified in about 30% of breast tumors, and ERBB2 amplification emerged as a significant predictor of both overall survival and time to relapse in patients with breast cancer [reviewed in (1)]. The gene discussed is ERBB2; the disease is breast neoplasm.